Background: The delegation of medical tasks (DMT) plays a significant role in the everyday practice of inpatient care but also presents a potential challenge in interprofessional collaboration. Assessing the conditions of DMT in everyday work is crucial to identify areas for optimization.

Methods: In a nationwide exploratory study, physicians, nursing and allied health professionals working for inpatient care facilities were surveyed regarding various aspects of DMT using a standardized online questionnaire.

Results: The majority of the 757 participants (64.9% physicians), perceived DMT to be both economically and time-efficient (88.5% agreement) and in the best interest of patients (74%). For 78.7% of the respondents, DMT represents a potential conflict in their daily work, depending on the quality of interprofessional communication. Inadequate staffing was identified as a barrier to a broader implementation of DMT by 83.8% of participants. 63.2% of the participants considered their knowledge of legal aspects related to DMT to be at least good (participants with less than 5 years of professional experience: 52.6%). Physicians primarily acquire relevant knowledge through professional practice (71.3% vs. non-physicians 39.5%).

Conclusion: Across the different professional groups DMT was considered beneficial and serving the interests of patients. Targeted promotion of safe and cost-effective DMT should be incorporated into medical education. Achieving greater benefits from DMT requires explicit legal frameworks, effective communication within the team and, in particular, adequate staffing among the professional groups responsible for delegated tasks.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.zefq.2024.01.007DOI Listing

Publication Analysis

Top Keywords

dmt
10
medical tasks
8
everyday work
8
inpatient care
8
aspects dmt
8
professional groups
8
[practice challenges
4
challenges delegating
4
delegating medical
4
tasks interprofessional
4

Similar Publications

Mapping mitochondrial morphology and function: COX-SBFSEM reveals patterns in mitochondrial disease.

Commun Biol

January 2025

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.

Mitochondria play a crucial role in maintaining cellular health. It is interesting that the shape of mitochondria can vary depending on the type of cell, mitochondrial function, and other cellular conditions. However, there are limited studies that link functional assessment with mitochondrial morphology evaluation at high magnification, even fewer that do so in situ and none in human muscle biopsies.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

RxY, New York, NY, USA.

Background: Disease-modifying therapies (DMTs) such as lecanemab and aducanumab are recommended for the treatment of patients with confirmed Alzheimer's disease (AD) within the mild cognitive impairment (MCI) or mild stages of dementia. Biomarker testing is required to confirm the presence of amyloid beta for prescription of DMTs. Confirmatory diagnosis at the MCI stage is important to take advantage of the narrow treatment window of currently available DMTs.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.

Background: Blood-based biomarkers (BBM) for Alzheimer's disease (AD) may be able to identify individuals eligible for emerging anti-amyloid treatments (DMT). We aimed to evaluate how to use BBM as (pre-) selection tools for DMTs by simulating different triaging scenarios in a memory clinic setting.

Methods: We included 1199 participants from the Amsterdam Dementia Cohort with measured BBM (plasma pTau181, GFAP and NfL) and used a predefined Youden-index based cut point for amyloid positivity (method: https://doi.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.

Several new blood-based biomarkers (BBMs) of Alzheimer's disease and related neuropathologies have completed late-stage validation and are beginning to be used in the clinical setting. However, the role of BBMs in various clinical settings, especially their specific context-of-use, remains an open question for the field. Several studies are beginning to systematically collect information on BBM real-word diagnostic performance, but as BBMs transition from research settings to clinical implementation, experience from clinical providers in specialty centers can inform and guide use.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

Karolinska Institutet, Solna, Stockholm, Sweden.

Background: Recent developments in blood biomarkers (BBM) have shown promising results in diagnosing amyloid pathology in Alzheimer's Disease (AD). However, information on how these BBMs can best be used in clinical settings to optimise clinical decision-making and long-term health outcomes for individuals with AD is still lacking. We aim to assess the potential clinical and economic value of BBM in AD diagnosis within the context of disease-modifying treatment (DMT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!